5th Floor, Rajapushpa Summit
Nanakramguda Rd, Financial District, Gachibowli
Hyderabad, Telangana - 500008
The Biopharmaceuticals Market is segmented by product type (monoclonal antibodies, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, vaccines, recombinant enzymes, cell and gene therapies, synthetic immunomodulators, and other product type), therapeutic application, and geography
Fastest Growing Market:
The global biopharmaceuticals market is found witnessing a CAGR of 7.32%. The market is largely driven by the growing geriatric population, increasing burden of chronic diseases, and rising inclination toward targeted therapy. Also, the huge demand of biopharmaceutical is facilitated by an accelerating focus in research and related investment.
The ability of biopharmaceutical products to address previously untreatable conditions has introduced innovative drugs in the market. About 70% of the potential medicines in development represent novel approaches to addressing diseases in areas, such as neurology, cancer, diabetes, and immunology. Biopharmaceuticals have thus seen to reduce the number of deaths due to cancer and HIV/AIDS in the past decade, which has led to an increase in the adoption of biopharmaceuticals in the global market.
In addition, the market demand for biopharmaceuticals is increasing with the rising desire to circumvent both the side-effects associated with some small-molecule therapeutics and invasive surgical treatments. However, high cost, along with the difficulty of the development of a biopharmaceutical drug, is one growth limiting factor.
As per the scope of the report, biopharmaceutical refers to any biologically synthesized molecule that is used to treat or manage disorders. Biopharmaceutical products include (but are not limited to) monoclonal antibodies, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, vaccines, recombinant enzyme, synthetic immunomodulators, cell and gene therapies, and other products.
|By Product Type|
|By Therapeutic Application|
|Inflammatory and Infectious Diseases|
Report scope can be customized per your requirements. Click here.
Among the given segments, monoclonal antibodies are believed to have the largest market size. This can be attributed to the growing research done with the help of monoclonal antibodies. On the other hand, the recombinant enzymes segment is expected to show rapid growth during the forecast period.
Monoclonal antibodies (mAbs) find their application in the areas of cancer treatment. Their use is becoming prevalent in developed countries, such as the United States and the United Kingdom. The mAb drugs in oncology are gaining momentum and growing at a decent pace. The segment is dominating the market currently, and the trend is expected to be followed in the future.
The recombinant enzymes, such as Enterokinase, are gaining attraction because of their efficacy in the digestion of the dietary proteins. This application has improved the market scope for this particular enzyme in the recent years.
To understand key trends, Download Sample Report
North America currently dominates the market for biopharmaceuticals, and is expected to continue its stronghold for a few more years. The United States has shown an incredible growth over the past several years. The country has been recognized as the innovation capital of the world for life sciences, and it is involved in global capital investments in the early stages of biopharmaceutical companies.
The United States holds the majority of the market in the North American region; this is due to the increasing prevalence of chronic diseases. In addition, there is a rise in per capita health expenditure in the country that is expected to increase over the forecast period, owing to the decrease in the unemployment rate.
To understand geography trends, Download Sample Report.
The biopharmaceuticals market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products with less prices. Companies, like Amgen Inc., Eli Lily & Company, Johnson & Johnson, and Pfizer Inc. hold a significant share in the biopharmaceuticals market.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Acceptance for Biopharmaceuticals
4.2.2 Ability of Biopharmaceuticals to Treat Previously Untreatable Diseases
4.2.3 Huge Market Demand
4.3 Market Restraints
4.3.1 High-end Manufacturing Requirements
4.3.2 Complicated and Cumbersome Regulatory Requirements
5. MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Monoclonal Antibodies
220.127.116.11 Anti Cancer Monoclonal Antibodies
18.104.22.168 Anti-inflammatory Monoclonal Antibodies
22.214.171.124 Other Monoclonal Antibodies
5.1.2 Recombinant Growth Factors
126.96.36.199 Granulocyte Colony Stimulating Factor
5.1.3 Purified Proteins
188.8.131.52 Leukemia Inhibitory Factor (LIF)
184.108.40.206 P53 Protein
220.127.116.11 P38 Protein
18.104.22.168 Other Purified Proteins
5.1.4 Recombinant Proteins
22.214.171.124 Serum Albumin
126.96.36.199 Amyloid Protein
5.1.5 Recombinant Hormones
188.8.131.52 Recombinant Human Growth Hormones
184.108.40.206 Recombinant Insulin
220.127.116.11 Other Recombinant Hormones
18.104.22.168 Recombinant Vaccines
22.214.171.124.1 Cancer Vaccines
126.96.36.199.2 Malaria Vaccines
188.8.131.52.3 Ebola Vaccine
184.108.40.206.4 Hepatitis B Vaccine
220.127.116.11.5 Tetanus Vaccine
18.104.22.168.6 Diptheria Vaccine
22.214.171.124.7 Cholera Vaccine
126.96.36.199.8 Other Recombinant Vaccines
188.8.131.52 Conventional Vaccines
184.108.40.206.1 Polio Vaccine
220.127.116.11.2 Pox Vaccine
18.104.22.168.3 Other Conventional Vaccines
5.1.7 Recombinant Enzymes
5.1.8 Cell and Gene Therapies
22.214.171.124 Allogeneic Products
126.96.36.199 Autologous Products
188.8.131.52 Acellular Products
5.1.9 Synthetic Immunomodulators
184.108.40.206 Cytokines, Interferones, Interleukins
5.1.10 Other Product Types
220.127.116.11 Blood Factors
18.104.22.168 Other Product Types
5.2 By Therapeutic Application
5.2.2 Inflammatory and Infectious Diseases
5.2.3 Autoimmune Disorders
5.2.4 Metabolic Disorders
5.2.5 Hormonal Disorders
5.2.6 Cardiovascular Diseases
5.2.7 Neurological Diseases
5.2.8 Other Diseases
5.3.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle-East & Africa
5.3.5 South America
126.96.36.199 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbvie Inc.
6.1.2 Amgen Inc.
6.1.3 Bristol-Myers Squibb Company
6.1.4 Eli Lily & Co.
6.1.5 Johnson & Johnson
6.1.6 Novartis AG
6.1.7 Novo Nordisk Inc.
6.1.8 Pfizer Inc.
6.1.9 GlaxoSmithKline PLC
6.1.10 F. Hoffmann-La Roche AG
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments